Serina raises $10M to develop SER-252 for advanced Parkinson’s
Goal: Advance lead therapy into Phase 1 testing in patients by mid-2025.
Serina Therapeutics has secured $10 million in new funding to support the development of its lead product, SER-252 (POZ-apomorphine), for treating advanced Parkinson’s disease.
The goal, according to a company press release, is to advance the candidate therapy toward a Phase 1 clinical trial in patients by mid-2025.
“SER-252 leverages strategic partner Enable Injections’ enFuse wearable drug delivery platform to enhance patient comfort and convenience, providing treatment to patients via an easy-to-administer, long-acting subcutaneous under-the-skin injection without skin reactions,” Serina stated.
The funds are from an equity financing agreement with strategic shareholder JuvVentures.
About Serina Therapeutics
Serina Therapeutics is a privately held biotechnology company located in Huntsville, Alabama. We have developed a proprietary, clinically-validated polymer technology based on the water-soluble polymer poly(oxazoline). We call it POZ for short. Our proprietary POZ platform is based on a synthetic, water soluble, low viscosity polymer called poly (2-oxazoline). During the synthesis steps, a predictable amount of drug is incorporated on the backbone of the polymer using pendant alkyne groups and metal catalyzed “click chemistry”.
POZ technology provides greater control in drug loading, and the rate of release of attached drugs can often be more precisely controlled. Drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood. The technology is optimized for small molecules and can also be applied to proteins, aptamers and other classes of molecules.
